

Number of shares and votes in Oncopeptides

STOCKHOLM – June 28, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 238,107 class C shares in Oncopeptides to a total 238,107 ordinary shares, in order to deliver ordinary shares to participants in Oncopeptides' incentive program Board SHP 2023.

As of today, the total number of shares in Oncopeptides amounts to 215,186,246 shares, of which 211,263,903 are ordinary shares and 3,922,343 are class C shares. As of today, the number of votes in Oncopeptides amounts to 211,656,137.19, and the share capital amounts to SEK 23,909,583.859895.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: david.augustsson@oncopeptides.com

Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-06-28 08:00 CEST.

About Oncopeptides

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com

Attachments

[Number of shares and votes in Oncopeptides](#)